It is a great pleasure to announce, that we have executed the contract on NSGO-CTU sponsored phase II randomized trial with Apexigen. The name of the trial will be ENGOT.OV64/NSGO-CTU-SOLERO. This is great news since it is the first trial globally in ovarian cancer evaluating a CD40 agonist with or without radiation therapy in ovarian cancer. Thank you Christina Dahl, Project Manager NSGO-CTU and Pernille Albrechtsen, Project Manager NSGO-CTU for your hard work on this trial. To read more about this, click here. The following colleagues around the world in the ENGOT are collaborating with us on the SOLERO trial: SwissGO (Switzerland), GEICO (Spain), BGOG (Belgium and Luxembourg) CEEGOG (Central and Eastern European Gynecologic Oncology Group).